Back to Press Releases

Acessa Health Presents at Congressional Black Caucus

Sarah Gettes | September 23, 2018

Congressional Black Caucus 2018 – Acessa Health Partners With The White Dress Project To Present On Healthcare Disparities And Uterine Fibroids.

 

September 13, 2018–AUSTIN, TX – Health Inc., developer of the Acessa System®, announced today it is continuing its collaboration with The White Dress Project, a nonprofit group that promotes fibroid awareness and advocacy, to present a session at this year’s Congressional Black Caucus Annual Legislative Conference.This Caucus covers Exclusive Coverage of Healthcare Policy, Patient Access, Outcomes and Disparities in Treatment, Which Impact African American Women.

“We are focused on ensuring that women have access to all available treatment options for their uterine fibroids. Unfortunately, there is a well-established racial barrier to women receiving less invasive alternatives to hysterectomy and this joint session aims to elevate the discussion among civil leaders surrounding this disparity,” said Acessa Health President and CEO Kim Rodriguez.

The current racial disparities impacting uterine fibroids are significant and well established in medical literature. As an example, among women who underwent hysterectomy for benign indications, African American women were less likely to receive a minimally invasive hysterectomy compared to white women. They were also 40% more likely to develop complications, nearly three times as likely to have a long hospital stay, and three times as likely to die, even though African American women were younger on average1,2.

Tanika Gray Valbrun, founder of The White Dress Project, noted, “As a community we need to begin to address and change the clear, systematic and structural defect within the US healthcare system that disproportionately pushes women of color toward the most invasive option, which is hysterectomy.”

This session will bring together leaders such as Adrianna Hopkins, host of Good Morning Washington and fibroids patient; Dr. Alicia Christy, Deputy Director of Reproductive Health at the Veterans Administration; Dr. Nicole Williams from The Gynecology Institute of Chicago; and Patient Ambassadors from The White Dress Project, Rashetta Fairnot and Jennifer Branison.

“This multi-stakeholder panel brings together the perspectives of patients, physicians and policy makers to begin tackling this complex topic,” said Dr. Nicole Williams, Founder and CEO of The Gynecology Institute of Chicago. “I am honored to be included in this panel and I believe that in order to effect change we need to open discussions about what is contributing to the overuse of hysterectomy to treat fibroids.”

About Acessa Health Inc.

Acessa Health is a women’s health innovator dedicated to advancing minimally invasive, uterine-sparing solutions for women with symptomatic fibroids. The company introduced the use of radiofrequency ablation for the treatment of uterine fibroids and is continuing to develop technologies that improve the lives of its patients. Acessa Health’s headquarters are in Austin, TX. For more information, visit AcessaProcedure.com

Sources:

1 Rosemarie B. Hakim, PhD, M. Beth Benedict, DrPH, JD, and Nancy J. Merrick, MD, MSPH, Quality of Care for Women Undergoing a Hysterectomy: Effects of Insurance and Race/Ethnicity, Am J Public Health. 2004 August; 94(8): 1399–1405.

2 Whitney R. Robinson, Mariah M. Cheng, Annie Green Howard, William R. Carpenter, Wendy R. Brewster and Kemi M. Doll, For U.S. Black women, shift of hysterectomy to outpatient settings may have lagged White women: a claims-based analysis, 2011–2013, BMC Health Serv Res. 2017; 17: 526.

 

The Acessa ProVu system is cleared by the FDA for the treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance.

The Acessa procedure is generally safe but complications may occur and can be serious. Risks and complications associated with the Acessa procedure include, but are not limited to: skin burns from the dispersion of radiofrequency energy, mild intra‐operative bleeding, transient urinary retention or urinary tract infection, adhesion formation, post‐procedural discomfort (cramping, pelvic pain), and transient amenorrhea, infection, injury to adjacent structures, vaginal bleeding and temporary anemia, blood loss requiring transfusion or hysterectomy, pneumothorax, wound dehiscence, deep vein thrombosis and pulmonary embolus, treatment failure, and complications related to laparoscopy and/or general anaesthesia including death.

Insufficient data exists on which to evaluate the safety and effectiveness of Acessa procedure in women who plan future pregnancy. Therefore, the Acessa procedure is not recommended for women who are planning future pregnancy. There is limited data regarding pregnancy following the Acessa procedure, if you become pregnant following the Acessa procedure, you should contact your doctor immediately.

Please consult with your doctor to understand the risks and benefits of surgery and find out if Acessa may be right for you. Rx Only.